GlassScriptPhysician profile
Joseph T Conroy
NPI 1265437834
$11,828.94
in general payments reported to CMS, 2019-2025
33 companies · $356 in 2025
The $356 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,195 · 2020: $991 · 2021: $1,800 · 2022: $1,652 · 2023: $2,158 · 2024: $677 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,191.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,963.61 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $1,861.05 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,549.35 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,159.90 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $742.85 | 2019-2025 | Jardiance |
| Pfizer INC. | $651.82 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $642.21 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $620.82 | 2019-2022 | |
| Amgen INC. | $496.21 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $296.80 | 2021-2023 | Cobalt Dr Mri Surescan, Micra |
| Astrazeneca Pharmaceuticals LP | $287.01 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $272.13 | 2021-2024 | Verquvo |
| Boston Scientific Corporation | $201.41 | 2019-2024 | Watchman Flx, Watchman Access System |
| Novo Nordisk INC | $181.78 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Regeneron Healthcare Solutions, INC. | $145.03 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $72.29 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $69.73 | 2019-2021 | |
| Akcea Therapeutics, INC. | $68.41 | 2019-2020 | |
| Esperion Therapeutics, INC. | $59.43 | 2020-2023 | Nexletol |
| Impulse Dynamics (USA) INC. | $56.06 | 2021-2022 | |
| Heartflow, INC. | $50.53 | 2023 | Ffrct |
| Irhythm Technologies, INC. | $48.69 | 2024 | Zio Monitor, Zio Xt Patch |
| Janssen Biotech, INC. | $45.42 | 2020-2021 | |
| Abbott Laboratories | $43.57 | 2019-2023 | Cardiomems |
| Philips North America LLC | $42.81 | 2020 | |
| Arbor Pharmaceuticals, INC. | $42.78 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $33.17 | 2019 | |
| Kestra Medical Technology Services, INC. | $25.01 | 2022 | |
| Ionis Pharmaceuticals, INC. | $23.17 | 2025 | Tryngolza |
| Alnylam Pharmaceuticals INC. | $22.14 | 2024 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $20.92 | 2022 | |
| Edwards Lifesciences Corporation | $18.17 | 2019 | |
| Medicomp INC | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Conroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.